Prospective clinical trial testing COXEN-based gene expression models of chemosensitivity in dogs with spontaneous osteosarcoma
Autor: | Keagan P. Collins, Sunetra Das, Daniel L. Gustafson, Kristen M. Weishaar, Dawn L. Duval, E. J. Ehrhart, Douglas H. Thamm, Jared S. Fowles |
---|---|
Rok vydání: | 2021 |
Předmět: |
Pharmacology
Oncology Cancer Research medicine.medical_specialty medicine.diagnostic_test business.industry Cancer Toxicology medicine.disease Carboplatin Gene expression profiling Clinical trial chemistry.chemical_compound chemistry Internal medicine Biopsy Medicine Osteosarcoma Pharmacology (medical) Doxorubicin business Prospective cohort study medicine.drug |
Zdroj: | Cancer Chemotherapy and Pharmacology. 88:699-712 |
ISSN: | 1432-0843 0344-5704 |
Popis: | This study is a prospective clinical trial in dogs with osteosarcoma testing a gene expression model (GEM) predicting the chemosensitivity of tumors to carboplatin (CARBO) or doxorubicin (DOX) developed using the COXEN method. Sixty dogs with appendicular osteosarcoma were enrolled in this trial. RNA isolation and gene expression profiling were conducted with 2 biopsies for 54/63 screened tumors, and with a single biopsy for 9 tumors. Resulting gene expression data were used for calculation of a COXEN score for CARBO and DOX based on a previous study showing the significance of this predictor on patient outcome utilizing retrospective data (BMC Bioinformatics 17:93). Dogs were assigned adjuvant CARBO, DOX or the combination based on the results of the COXEN score following surgical removal of the tumor via amputation and were monitored for disease progression by chest radiograph every 2 months. The COXEN predictor of chemosensitivity to CARBO or DOX was not a significant predictor of progression-free interval or overall survival for the trial participants. The calculation of DOX COXEN score using gene expression data from two independent biopsies of the same tumor were highly correlated (P |
Databáze: | OpenAIRE |
Externí odkaz: |